KR20240004802A - 오렉신 수용체 효능제 및 그의 용도 - Google Patents
오렉신 수용체 효능제 및 그의 용도 Download PDFInfo
- Publication number
- KR20240004802A KR20240004802A KR1020237041381A KR20237041381A KR20240004802A KR 20240004802 A KR20240004802 A KR 20240004802A KR 1020237041381 A KR1020237041381 A KR 1020237041381A KR 20237041381 A KR20237041381 A KR 20237041381A KR 20240004802 A KR20240004802 A KR 20240004802A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- mmol
- cycloalkyl
- compound
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183321P | 2021-05-03 | 2021-05-03 | |
| US63/183,321 | 2021-05-03 | ||
| PCT/EP2022/061851 WO2022233872A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240004802A true KR20240004802A (ko) | 2024-01-11 |
Family
ID=81940742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237041381A Pending KR20240004802A (ko) | 2021-05-03 | 2022-05-03 | 오렉신 수용체 효능제 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240254143A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4334323A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516033A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240004802A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117616030B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022269811A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023022050A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3217403A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308099A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012971A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202309051A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022233872A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス,インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| US20240425519A1 (en) * | 2021-11-04 | 2024-12-26 | University Of Washington | Novel spirocyclic compounds as klhdc2 ligands |
| JP2026506356A (ja) | 2023-01-31 | 2026-02-24 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 大環状オレキシン受容体アゴニスト及びその使用 |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0687268B1 (en) * | 1993-03-04 | 1998-05-27 | Pfizer Inc. | Spiroazacyclic derivatives as substance p antagonists |
| EP0997464B1 (en) * | 1998-10-23 | 2005-02-16 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| US8530648B2 (en) * | 2009-12-21 | 2013-09-10 | Novartis Ag | Diaza-spiro[5.5]undecanes |
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| SG11201806429PA (en) * | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| US11655241B2 (en) * | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2022
- 2022-05-03 MX MX2023012971A patent/MX2023012971A/es unknown
- 2022-05-03 WO PCT/EP2022/061851 patent/WO2022233872A1/en not_active Ceased
- 2022-05-03 KR KR1020237041381A patent/KR20240004802A/ko active Pending
- 2022-05-03 JP JP2023567888A patent/JP2024516033A/ja active Pending
- 2022-05-03 CA CA3217403A patent/CA3217403A1/en active Pending
- 2022-05-03 TW TW111116714A patent/TW202309051A/zh unknown
- 2022-05-03 IL IL308099A patent/IL308099A/en unknown
- 2022-05-03 AU AU2022269811A patent/AU2022269811A1/en active Pending
- 2022-05-03 EP EP22727800.9A patent/EP4334323A1/en active Pending
- 2022-05-03 BR BR112023022050A patent/BR112023022050A2/pt unknown
- 2022-05-03 CN CN202280045968.9A patent/CN117616030B/zh active Active
- 2022-05-03 US US18/558,245 patent/US20240254143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022233872A1 (en) | 2022-11-10 |
| EP4334323A1 (en) | 2024-03-13 |
| CA3217403A1 (en) | 2022-11-10 |
| TW202309051A (zh) | 2023-03-01 |
| CN117616030B (zh) | 2026-06-19 |
| CN117616030A (zh) | 2024-02-27 |
| IL308099A (en) | 2023-12-01 |
| JP2024516033A (ja) | 2024-04-11 |
| MX2023012971A (es) | 2024-01-16 |
| AU2022269811A1 (en) | 2023-11-16 |
| US20240254143A1 (en) | 2024-08-01 |
| BR112023022050A2 (pt) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516033A (ja) | オレキシン受容体アゴニスト及びその使用 | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| EP4284365A1 (en) | Cdk2 inhibitors and methods of using the same | |
| CA2944475A1 (en) | Bicyclic-fused heteroaryl or aryl compounds | |
| WO2021170631A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| WO2021204801A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| CN117645606A (zh) | 受体抑制剂、包含其的药物组合物及其用途 | |
| WO2022152852A1 (en) | Antagonists of mrgx2 | |
| WO2024148029A2 (en) | Organic compounds as nlrp3 inhibitors | |
| AU2016258087A1 (en) | Tricyclic sulfones as ROR¿ modulators | |
| US20240360081A1 (en) | Sulfonamide orexin receptor agonists and uses thereof | |
| TW202515541A (zh) | 補體因子b抑制劑及其用途 | |
| US20260042755A1 (en) | Gpr6 inverse agonists | |
| TW202412784A (zh) | 氮-喹唑啉化合物及使用方法 | |
| CA2832334A1 (en) | New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds | |
| US20250320227A1 (en) | Macrocyclic orexin receptor agonists and uses thereof | |
| EP4558481A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
| TW202444724A (zh) | 大環食慾激素受體促效劑及其用途 | |
| WO2025245351A1 (en) | Substituted aryl sulfonamides and compositions and uses thereof | |
| TW202508566A (zh) | Kv1.3鉀通道拮抗劑 | |
| HK40029777A (en) | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof | |
| HK1165418B (en) | Azetidines as histamine h3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231130 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250502 Comment text: Request for Examination of Application |